Pulmonary Cell News Volume 4.45 | Nov 19 2015

Role of Pro-inflammatory Cytokines in Radiation-Induced Genomic Instability in Human Bronchial Epithelial Cells
Scientists investigated whether IL-8 induction is part of a broader pro-inflammatory response produced by epithelial cells in response to damage, which influences genomic instability measured by increased micronuclei and DNA repair foci frequencies. [Radiat Res] Abstract

Nontypeable Haemophilus influenzae Exploits the Interaction between Protein-E and Vitronectin for the Adherence and Invasion to Bronchial Epithelial Cells
The authors hypothesized that protein-E, an outer membrane protein of nontypeable H. influenzae (NTHi), plays a role in this penetration into bronchial epithelial cells. NTHi strains invaded bronchial epithelial cells and the intracellular bacteria were localized in early endosomes. [BMC Microbiol] Full Article

LUNG CANCER

Overexpression of Major CDKN3 Transcripts Is Associated with Poor Survival in Lung Adenocarcinoma
The authors analyzed cyclin-dependent kinase inhibitor 3 (CDKN3) expression and its association with patient survival in three cohorts of lung adenocarcinoma. CDKN3 transcripts were further analyzed in a panel of cell lines and lung adenocarcinoma tissues. [Br J Cancer] Abstract

miR-411 Contributes the Cell Proliferation of Lung Cancer by Targeting FOXO1
Scientists found miR-411 was overexpressed in lung cancer cells; overexpression of miR-411 promoted anchorage-dependent and anchorage-independent growths of lung cancer, while miR-411 knockdown reduced this effect. [Tumor Biol] Abstract

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Researchers described the establishment and characterization of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant non-small cell lung cancer (NSCLC) cell lines and a pilot study on the effects of a combined MET and EGFR inhibitors treatment. [PLoS One] Full Article

Tangeretin Derivative, 5-Acetyloxy-6,7,8,4′-Tetramethoxyflavone Induces G2/M Arrest, Apoptosis and Autophagy in Human Non-Small Cell Lung Cancer Cells In Vitro and In Vivo
The authors investigated the anticancer effects of 5-acetyloxy-6,7,8,4′-tetramethoxyflavone on CL1-5 non-small cell lung cancer cells both in vitro and in vivo. [Cancer Biol Ther] Abstract

Digitoxin and Its Synthetic Analog MonoD Have Potent Antiproliferative Effects on Lung Cancer Cells and Potentiate the Effects of Hydroxyurea and Paclitaxel
Investigators evaluated the in vitro antiproliferative activity of the cardiac glycoside digitoxin and its synthetic analog MonoD on H460 lung cancer cells grown under different culture conditions. [Oncol Rep] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

PTC Completes Enrollment of Phase III Clinical Trial of Translarna™ for Patients with Cystic Fibrosis
PTC Therapeutics, Inc. announced that it has completed enrollment of ACT CF, the company’s second Phase III clinical trial of Translarna™ for patients with nonsense mutation cystic fibrosis. [PTC Therapeutics, Inc.] Press Release

Lilly and Merck Expand Immuno-Oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Eli Lilly and Company and Merck announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA^® and Merck’s KEYTRUDA^® in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer. [Eli Lilly and Company] Press Release

Nivolumab in Non-Small Cell Lung Cancer: Indication of Major Added Benefit for Under-75-Year-Olds
The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether nivolumab offers an added benefit over the appropriate comparator therapy in the treatment of non-small cell lung cancer. [Institute for Quality and Efficiency in Health Care] Press Release

Tagrisso™ (Osimertinib) (AZD9291) Approved by the US FDA as Treatment for Patients with EGFR T790M Mutation-Positive Metastatic Non-Small Cell Lung Cancer
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved TAGRISSO™ 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. [AstraZeneca] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

Postdoctoral Fellow – Cancer Biology (Cold Spring Harbor Laboratory)

Professorship – Respiratory Science (University of Cambridge)

Postdoctoral Positions – Fibrotic Remodeling of the Lung (University of Vermont)

Postdoctoral Positions – Cancer (University of Texas MD Anderson Cancer Center)

Post-Doctoral Fellow – Lung Microbiome Research and Asthma (University of Michigan)

PhD Studentships – Cancer Research (University of Cambridge)

Postdoctoral Position – Pulmonary Research (Helmholtz Association)

Postdoctoral Position – Lung Biology Research (University of Southern California)

Postdoctoral Fellowship – Developmental Cell Biology and Regenerative Medicine (University of California San Francisco)

Postdoctoral Researcher – Molecular Mechanisms of Pulmonary Diseases (Eastern Virginia Medical School)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.